Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106925 · ClinicalTrials.gov registry record
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
A clinical trial of Graft Vs Host Disease and Graft Rejection, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT00106925 is a study of Graft Vs Host Disease and Graft Rejection that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1,000 participants, above the 110-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (809% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00106925, a study of Graft Vs Host Disease and Graft Rejection, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center. Patients are monitored for their response to treatment, disease relapse, and later-occurring effects of the transplant. Patients between 10 and 80 years of age who received a donor stem cell transplant at the NIH Clinical Center under an NHLBI protocol may be eligible for this study. Candidates must have had their first transplant at least 3 years before entering the current study. Participants are generally seen in the clinic every 12 months for some or all of the following procedures: * Periodic physical examinations, eye examinations, and blood and urine tests. * Bone marrow aspiration and biopsy: A sample of bone marrow is obtained for microscopic examination. The patient is given local anesthesia or conscious sedation. An area of the hipbone is numbed, a thin needle is inserted through the skin into the bone, and a small amount of marrow is withdrawn. * Tissue biopsy: A small piece of tissue or tumor is obtained for microscopic examination. Depending on the site of the biopsy, the tissue may be removed using a cookie cutter-like "punch" instrument, a needle, or a knife. The area is numbed and the tissue is removed with the appropriate tool. * Imaging tests to visualize organs, tissues, and cellular activity in specific tissues. For these tests, the patient lies on a table that slides into the scanner. They may include the following: 1. Nuclear scans use a sensitive camera to track a small amount of radioactive material (radioisotope) that is given to the patient by mouth or through a vein. The scan may show abnormal areas of tissue in the bones, liver, spleen, kidney, brain, thyroid, or spine. 2. Magnetic resonance imaging (MRI) uses a magnetic field and radio waves to examine small sections of body organs and tissues. 3. Computerized tomography (CT) uses x-rays and can be done from different ang
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2005-04-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106925
The ClinicalTrials.gov registry entry for NCT00106925 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 110-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (809% higher). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Graft Vs Host Disease appearing as the primary indexed condition, and to 0 interventions.
NCT00106925 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00106925 about?
NCT00106925 is a clinical study titled "Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants". This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center. Patients are monitored for their response to treatment, disease relapse, and later-occurring effects of the transplant. Patients between 10 a...
What is the current status of trial NCT00106925?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2005-04-22.
What conditions does trial NCT00106925 study?
This clinical trial studies the following conditions: Graft Vs Host Disease, Graft Rejection, Graft-versus-leukemia.
Who is sponsoring clinical trial NCT00106925?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00106925 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
RECRUITING
-
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
RECRUITING · NA
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.